4:12 PM
 | 
Dec 23, 2013
 |  BC Extra  |  Top Story

UTHR jumps on oral PAH drug approval

United Therapeutics Corp. (NASDAQ:UTHR) jumped $26.67 (30%) to $114.51 on Monday after FDA approved a resubmitted NDA for oral Orenitram treprostinil to treat pulmonary arterial hypertension (PAH). The company already markets IV and subcutaneous formulations of the synthetic long-acting stable prostacyclin...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >